Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26420705 | 0.90 | CYP1A2 (0.31) | CYP1A2CYP2D6 | |
| SCHEMBL19779774 | 0.87 | CYP1A2 (0.37) | CYP1A2CYP2D6CYP2C9HPGDMAPK1 | |
| SCHEMBL25565974 | 0.86 | HRH3 (0.31) | — | |
| SCHEMBL26177002 | 0.85 | HRH3 (0.33) | — | |
| SCHEMBL19880427 | 0.83 | CYP1A2 (0.37) | CYP1A2CYP2D6CYP2C9HPGDMAPK1 | |
| SCHEMBL19781528 | 0.80 | CYP1A2 (0.41) | CYP1A2CYP2D6CYP2C9HPGDMAPK1 | |
| SCHEMBL26427568 | 0.79 | MAPT (0.30) | — | |
| SCHEMBL23492771 | 0.76 | PLA2G1B (0.36) | CYP1A2CYP2D6 | |
| SCHEMBL26420702 | 0.76 | CYP1A2 (0.39) | CYP1A2CYP2D6CYP2C9HPGDMAPK1 | |
| SCHEMBL11762546 | 0.75 | CYP1A2 (0.50) | CYP1A2CYP2D6CYP2C9HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4130000-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUND | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| US-20210171492-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-06-10 | — | — | US | disclosed |
| US-10875839-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-06-18 | — | — | US | disclosed |
| US-10597377-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-24 | — | — | US | disclosed |
| US-10351547-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190002431-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2019-01-03 | — | — | US | disclosed |
| US-9896432-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9896432-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2018-01-18 | — | — | US | disclosed |
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | CYP1A2 4769/4885CYP2D6 4485/4885CYP2C9 4814/4885 |
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | CYP1A2 4769/4885CYP2D6 4485/4885CYP2C9 4814/4885 |
| US-10597377-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | CYP1A2 4769/4885CYP2D6 4485/4885CYP2C9 4814/4885 |
| US-10351547-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | CYP1A2 4769/4885CYP2D6 4485/4885CYP2C9 4814/4885 |
| US-20190002431-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | CYP1A2 4769/4885CYP2D6 4485/4885CYP2C9 4814/4885 |
| US-10875839-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | CYP1A2 4769/4885CYP2D6 4485/4885CYP2C9 4814/4885 |
| US-20210171492-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | CYP1A2 4769/4885CYP2D6 4485/4885CYP2C9 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.